Blood Podcast
Health, Fitness & Longevity
About
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
Episodes
- Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia
Dr. Alexis Thompson discusses the long-term efficacy and safety of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia. The study documented sustained transfusion independence for up to 10 years with a safety prof…
- Effects of ZNF467 on HSPC fitness and Promotion of Follicular Lymphoma via DC-SIGN
Dr. James Griffin interviews Drs. Bin Guo and Francesco Forconi about their Blood publications. Dr. Guo's research shows how ZNF467 influences hematopoietic stem cell engraftment through biomechanical reprogramming. Dr. Forconi discusses h…
- Pathophysiology of ANKRD26-related thrombocytopenia and B-ALL recurrence after blinatumomab
Drs. Shengwen Calvin Li and Hrishi Krishna Srinagesh discuss their research published in Blood. Dr. Li details findings on ANKRD26 thrombocytopenia, identifying abnormalities in progenitor expansion and apoptosis. Dr. Srinagesh presents da…
- Real-world availability of CAR T-cell therapies
Blood Podcast editor Laurie Sehn interviews Dr. Edward Cliff about his research on the global availability of CAR T-cell therapies. The study examines health technology assessment across G20 countries, highlighting disparities in access to…
- Consequences of p53 loss and Gastrin for aGVHD of the Stomach
This episode features Drs. Steffen Boettcher and Robert Zeiser discussing their research published in Blood. Dr. Boettcher explains how p53 loss can rescue bone marrow failure but increase leukemia risk, while Dr. Zeiser details gastrin's…
- Review Series on Myeloproliferative Neoplasms
Blood Associate Editor Dr. Jason Gotlib interviews Drs. Stefan Constantinescu, Ann Mullally, and Marina Kremyanskaya about recent advances in treating myeloproliferative neoplasms (MPNs). The discussion covers next-generation JAK inhibitor…
- CH in children with SCD and Asciminib for CML in the ASC4FIRST trial
In this Blood Podcast episode, Dr. Laura Michaelis interviews Drs. Alexander Bick and Jorge Cortes. They discuss asciminib's efficacy in the ASC4FIRST trial for newly diagnosed CML and the increased prevalence of clonal hematopoiesis in ch…
- Emerging Mechanisms: Neutrophils and Immune thrombocytopenia from ICI
This episode of the Blood podcast features an interview with Drs. Christian Gorzelanny and Rebecca Leaf. Dr. Gorzelanny discusses a new mechanism involving neutrophils and nanotubes in inflammatory disorders, while Dr. Leaf covers immune t…
- Hepcidin-DMT1 interaction and GPRC5D-targeting bispecific antibody for MM
Authors Drs. Marion Falabrègue and Ajai Chari discuss their Blood publications. Falabrègue's work explores manipulating the hepcidin-DMT1 interaction to affect iron absorption. Chari's research presents findings on a talquetamab and daratu…
- PETAL Consortium Survival Prognosticators and How Inflammation Impacts Hematopoiesis
Drs. Mark Sorial and Emmanuelle Passegue discuss their research published in Blood. Dr. Sorial covers survival prognosticators in T-cell lymphomas from the PETAL consortium, and Dr. Passegue explains how inflammation affects hematopoiesis…
- Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occulsions
This podcast episode reviews recent advances in understanding the structure and function of occlusive thrombi, covering topics like platelets and the contact system. It explores how new knowledge can inform future diagnostic and therapeuti…
- VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM
This episode features Blood editor Dr. Laurie Sehn interviewing Drs. Julie Jaffray and Ulrike Philippar. Dr. Jaffray discusses a venous thrombosis risk model for critically ill children, while Dr. Philippar covers a novel T-cell-engaging t…
- CAR-iNKT cell immunotherapy and Jagged2/Notch regulation of HSC
In this episode of the Blood Podcast, Dr. Laurie Sehn interviews Drs. Anastasios Karadimitris and Maria Carolina Florian. They discuss Dr. Karadimitris' research on CAR-iNKT cell immunotherapy for leukemia and Dr. Florian's findings on Jag…
- Biologic Insights and Clinical Trial Design for AML
In this episode of the Blood Podcast, Dr. James Griffin interviews Drs. Paresh Vyas and Andrew Hantel about their research on Acute Myeloid Leukemia (AML). They discuss insights into overcoming treatment resistance and the impact of modern…
- How I Treat Series on Acute Lymphoblastic Leukemia
Dr. Hervé Dombret interviews Drs. Sarah K. Tasian and David T. Teachey about their papers on treating Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) and early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)…
- How I Treat Series on the 25th anniversary of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Blood Podcast features a discussion on the How I Treat Series, celebrating 25 years of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. The episode covers CML management during relapse and pregnancy, and hematopoietic stem cell tran…
- How I Treat Series on Hematologic Complications in Pregnancy
Dr. Thomas Ortel interviews Drs. Ware Branch and J.J. Strouse about their papers on managing hematologic complications in pregnancy. Topics include diagnosing and treating antiphospholipid syndrome and sickle cell disease in pregnant patie…
- Review Series on Marginal Zone Lymphoma
This Blood Podcast episode features Dr. Philippe Armand interviewing Drs. Juan Pablo Alderuccio and Ariela Noy about their review on Marginal Zone Lymphoma. They discuss the heterogeneous nature of MZL and the need for more specific therap…
- VTE Recurrence Risk Factors and poor-response AML Transplant Outcome Indicators
Authors Dr. David-Alexandre Trégouët and Dr. Johannes Schetelig discuss their research on VTE recurrence risk factors and outcomes for poor-response AML transplant patients. Their studies, published in Blood journal, explore genomic eviden…
- Novel Treatment Targets for Hemophilia A and AML
This episode features Blood editor Dr. James Griffin interviewing Drs. Vincent Muczynski and Mark Geyer about their research. Dr. Muczynski investigates alternative gene therapy for hemophilia A, while Dr. Geyer explores CAR T cells target…
- Novel Differentiation Therapies for AML and Prognostic Value of PET in MM
Dr. Laurie Sehn interviews Drs. Vijay Sankaran, Ruud Delwel, and Françoise Kraeber-Bodere about novel differentiation therapies for AML targeting the MECOM gene and the prognostic significance of PET scan results in MM patients from the CA…
- Review Series on Platelet Heterogeneity
In this Blood Podcast Review Series episode, Dr. Elisabeth Battinelli, Blood Associate Editor, speaks with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai about Platelet Heterogeneity. The full review series is available in Bl…
- Special Episode: Maternal Health in Hematology
This special episode of the Blood Podcast features editor Dr. Laura Michaelis interviewing Dr. Arielle Langer and Dr. Marc Blondon. They discuss their featured articles on β-Thalassemia minor and pregnancy, and thrombotic biomarkers after…
- Analysis of IELSG37 Trial Results and PF4 in Stem Cell Aging
Drs. Emanuele Zucca and Sandra Pinho join Dr. James Griffin on the Blood Podcast to discuss their latest research. Dr. Zucca analyzes the IELSG37 trial, suggesting R-CHOP21 may be suboptimal for PMBCL. Dr. Pinho explores how megakaryocytic…
- Fixed-Duration Epcoritamab Combination Therapy for Relapsed or Refractory Follicular Lymphoma and Pre-Transplant Strategies for GVHD post-HSCT
Dr. Laurie Sehn interviews Drs. Lorenzo Falchi and Robert Levy about their Blood Journal papers. Dr. Falchi discusses epcoritamab for follicular lymphoma, and Dr. Levy presents findings on Treg expansion to ameliorate GVHD post-HSCT, both…
- Advancing Blood Disorder Treatments Through Precision Therapeutics
This episode features Drs. Terri Parker and Peter Lenting discussing advancements in blood disorder treatments. Dr. Lenting shares insights on a new bispecific antibody for von Willebrand disease, while Dr. Parker presents findings from a…
- New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials
This episode features research on how mitochondrial DNA may act as a first hit in transfusion-related acute lung injury and an analysis of venetoclax-obinutuzumab efficacy in CLL trials, questioning the impact of patient fitness.
- Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions
Dr. Laura Michaelis interviews Dr. Taylor Brooks about his Blood Journal paper on bispecific antibodies, epcoritamab and glofitamab, for aggressive B-cell lymphoma. The discussion covers real-world data from 245 patients with relapsed or r…
- Review Series on Follicular Lymphoma
Associate Editor Dr. Philippe Armand interviews authors about improving treatments for follicular lymphoma. Discussions cover managing relapsed/refractory disease, future strategies, and understanding disease transformation, referencing th…
- Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms
The Blood Podcast features Drs. Dhakal and Bierings discussing talquetamab as a bridging therapy for multiple myeloma and the identification of MADD gene variants linked to Von Willebrand disease type 1.
- Spotlight on Acute Myeloid Leukemia
In this Blood Podcast Spotlight episode, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl about their paper on treating older adults with Acute Myeloid Leukemia, discussing challenges and the need for less toxic therapie…
- Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments
This episode discusses a study comparing busulfan-melphalan conditioning with melphalan alone for transplant-eligible multiple myeloma. It also explores the use of spatial transcriptomics to understand the complex interactions within the m…
- How I Treat Wiskott-Alrich syndrome
In this episode of the Blood Podcast's 'How I Treat' series, Dr. Laura Michaelis interviews Dr. Sung-Yun Pai about the management of Wiskott-Aldrich syndrome. They discuss updated treatment approaches, challenges including late diagnosis a…
- Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas
This Blood Podcast episode discusses marstacimab for hemophilia A/B prophylaxis, highlighting its efficacy and safety in the BASIS trial. It also covers matched-donor allogeneic CD19 CAR-T for adult B-ALL and introduces the CLIPI prognosti…
- Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma
This episode discusses the link between Epstein-Barr virus genomic variants and human diseases like hematological malignancies. It also covers somatic GATA1 mutations in Down syndrome-associated leukemia and updated definitions for high-ri…
- Review Series on Acute Lymphoblastic Leukemia (ALL)
Dr. Hervé Dombret and Dr. Mark Litzow discuss recent immunotherapy advances for Acute Lymphoblastic Leukemia (ALL), noting innovative treatments like blinatumomab and inotuzumab that show high survival and remission rates, particularly in…
- Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML
This episode discusses the potential of Azacitidine in treating VEXAS syndrome, advancements in precision blood matching using array genotyping, and the identification of a new vulnerability in TP53-mutated AML related to BAP1 loss, which…
- Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations
This episode discusses persistent immune profile changes in diffuse large B-cell lymphoma survivors, the apparent lack of role for plasminogen activation in preventing venous thromboembolism, and a new mechanism for targeting hematological…
- “Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA
This episode of Blood Podcast discusses Tet2-mutant HSPC regulation via Ncoa4, the potential of the WU-CART-007 CAR T product for T-cell leukemia, and new genetic insights into classical Hodgkin lymphoma derived from ctDNA analysis.
- Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHD
This episode discusses targeting NPM1 in acute myeloid leukemia, with researchers reporting the first clinical evidence of menin inhibitor-induced complete remissions. It also covers targeting CD137 to prevent graft-versus-host disease usi…
- How I Treat Series on Iron Overload in Hematologic Disorders
Dr. Thomas Coates interviews Dr. Emanuele Angelucci regarding his paper on managing iron overload in hematopoietic cell transplantation. This discussion is part of Blood's 'How I Treat Series on Iron Overload in Hematologic Disorders'.
- Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor era
This episode covers predicting follicular lymphoma progression using PET and ctDNA, identifying immune hotspots in aplastic anemia, and the outcomes of allogeneic transplantation for Hodgkin lymphoma in the era of checkpoint inhibitors.
- Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction models for chronic myelomonocytic leukemia
This episode of the Blood Podcast discusses exogenous CD19 stimulation in CAR T-cell therapy for B-cell ALL, new sequential rapid immune-assays for HIT diagnosis, and resource-adaptive survival prediction models for CMML.
- How I Treat series on Acute Myeloid Leukemia
Drs. Luger, DiNardo, Wang, Wei, and Roboz discuss advances in Acute Myeloid Leukemia (AML) treatment, focusing on new combinations like Venetoclax-azacitidine and personalized care strategies.
- Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleeding
This episode of Blood Podcast covers three main topics: the effects of daratumumab maintenance on minimal residual disease in newly diagnosed multiple myeloma patients, the role of neutrophils in myeloproliferative neoplasms, and a genome-…
- Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia
This episode discusses enhanced hematopoietic stem cell transplantability. It also covers targeting the JAK-STAT pathway with ruxolitinib for macrophage activation syndrome and refractory anemia, and examines trials on magrolimab for newly…
- A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse
This episode discusses a JAK inhibitor, itacitinib, for preventing CRS and neurotoxicity in CAR T-cell therapy. It also covers the interaction between ChAdOx1 and platelets, potentially causing thrombosis, and explores lineage switch as a…
- Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor
This episode of Blood Podcast covers the use of ruxolitinib plus dexamethasone for adult hemophagocytic lymphohistiocytosis, explores lysine-specific demethylase-1 inhibitors for sickle cell disease, and discusses the clinical characterist…
- Review series on mantle cell lymphoma
Dr. Philippe Armand and Dr. Christine Ryan discuss the review series on mantle cell lymphoma, referencing their work on frontline management and the evolving landscape of treatments and research.
- Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas
This Blood Podcast episode discusses rapid, high-sensitivity ADAMTS13 assays for TTP, combination CD38/PD-1 blockade for extranodal NK/T-cell lymphoma showing durable responses, and a bispecific antibody overcoming a zombie enzyme in CREBB…